GSK-Moderna deal shows value of patent access in crowded vaccine market
By Steve Scherer ( November 12, 2026, 17:32 GMT | Comment) -- GSK and Moderna’s cross-license offers vaccine rivals a possible route through overlapping pipelines and uncertain patent litigation, lawyers told MLex. A pending US appeal could limit recovery against Moderna for government-supplied vaccines, adding a potential incentive to settle. The companies haven't disclosed what drove their agreement.For drugmakers competing in a market reshaped by the end of the Covid vaccine boom, access to a rival’s patents and relief from litigation uncertainty can be more valuable than continuing a legal fight, intellectual property lawyers told MLex, pointing to GSK and Moderna’s recent agreement to exchange patent rights....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.